Nutrition Care and Dietetic Practice in Managing Metabolic and Endocrine Dysfunction in Polyendocrine Metabolic Ovarian Syndrome (PMOS): Implications and Opportunities in the Context of the Name Change of Polycystic Ovarian Syndrome to PMOS.

Polyendocrine metabolic ovarian syndrome (PMOS) affects 8‒13% of women across the lifespan. Those with PMOS have reduced quality of life and increased risk of comorbidities, including elevated weight, eating disorders, gestational diabetes, type 2 diabetes, and cardiovascular disease. PMOS is a major population in clinical dietetic practice, and dietary intervention is the first-line approach recommended to target metabolic risk in the international evidence-based guidelines for assessment and management of polycystic ovary syndrome (PCOS). The past name, PCOS, was ovarian-centric and did not accurately reflect the pathophysiology, endocrine, or metabolic dysfunction of the syndrome. The new name, PMOS, has been determined by a rigorous global consensus process including 56 organizations, >14,000 survey responses, and consultation with experts and patients in workshops that identified the need for accurate medical representation of the syndrome and a stigma-reducing name. Dietitians encounter patients with PMOS with increased cardiometabolic risk who also experience high rates of elevated weight, weight stigma, and eating disorders. Nutrition care of patients with PMOS often involves managing these conditions, use of anti-obesity and diabetes medications, conferring with prescribing clinicians, and navigating patient goals and preferences. Improved recognition of the metabolic risks can strengthen alignment with dietary management approaches and referral to nutrition care services as part of the multidisciplinary care needed in those with PMOS. Dietitians can play a key role in managing nutritional misinformation, supporting patient health literacy and nutritional self-management. The new name can contribute to expanded opportunities for nutritional research that targets endocrine and metabolic outcomes to improve the clinical care, health, and well-being of those living with PMOS.